Individual Patient Compassionate Use of GX-I7
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 26, 2020
CompletedFirst Posted
Study publicly available on registry
February 28, 2020
CompletedMarch 17, 2022
March 1, 2022
February 26, 2020
March 2, 2022
Conditions
Interventions
patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks
Eligibility Criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Genexine, Inc.lead
Study Sites (1)
Kangnam St. Mary's Hospital
Seoul, 137-701, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 26, 2020
First Posted
February 28, 2020
Last Updated
March 17, 2022
Record last verified: 2022-03